E. Burd

Clinical Microbiology Reviews · 2003

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom E. Burd trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Mark Schiffman

Papers from E. Burd's perspective

Ordered by how strongly the researchers E. Burd trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. (Journal of the National Cancer Institute)
  2. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. (Journal of the National Cancer Institute)
  3. Practical statistics for medical research
  4. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. (The Lancet Oncology)
  5. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. (Journal of the American Medical Association (JAMA))
  6. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American… (Archives of Pathology & Laboratory Medicine)
  7. The 2001 Bethesda System: terminology for reporting results of cervical cytology. (Journal of the American Medical Association (JAMA))
  8. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical… (American Journal of Clinical Pathology)
  9. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer (Ca)
  10. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy… (The Lancet Oncology)

Their papers